Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Treasury Shares (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Treasury Shares for 9 consecutive years, with $976.7 million as the latest value for Q1 2026.

  • For Q1 2026, Treasury Shares rose 31.15% year-over-year to $976.7 million; the TTM value through Mar 2026 reached $976.7 million, up 31.15%, while the annual FY2025 figure was $966.6 million, 38.84% up from the prior year.
  • Treasury Shares hit $2.6 million in Q4 2025 for Corcept Therapeutics, up from $1.6 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $23.4 million in Q1 2023 and bottomed at $20000.0 in Q1 2024.
  • Average Treasury Shares over 5 years is $3.2 million, with a median of $1.2 million recorded in 2024.
  • Year-over-year, Treasury Shares surged 216.6% in 2022 and then increased 5.97% in 2024.
  • Corcept Therapeutics' Treasury Shares stood at $456.1 million in 2022, then soared by 39.23% to $635.1 million in 2023, then grew by 9.62% to $696.2 million in 2024, then surged by 38.84% to $966.6 million in 2025, then grew by 1.05% to $976.7 million in 2026.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $976.7 million, $966.6 million, and $923.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.